|
APRIL'S BEST FEATURED EDITORIAL |
|
|
Carolina Reapers: Fact-Checking The "Death" Of The US mRNA Industry | By Anna Rose Welch, editorial & community director, Advancing RNA | Welcome to Advancing RNA’s mRNA Hot Takes for our "Season Finale." Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to answer yet another loaded question: Are things in the U.S. for mRNA as bad as they truly seem? |
|
|
The Monster Under The Bed: Defining Potency In The mRNA Space | By Anna Rose Welch, editorial & community director, Advancing RNA | How are we defining and measuring our product’s potency? This question, posed at a past CASSS mRNA Symposium, is far from straightforward, and, dear reader, based on the resulting discussion amongst regulators and panel members, it became clear we have a lot of different definitions of what potency even is in the mRNA space. |
|
|
The Evolving CMC Landscape For mRNA-LNPs | By Advancing RNA Live | In this Advancing RNA Live clip, CMC consultant Sujit Jain unpacks the levels of maturity he’s observed in process and analytical development, as well as supply chain. While vaccines and liver-targeting therapeutics boast what we can call a reproducible platform today, targeted LNP therapies introduce a handful of scale-up sensitivities and characterization hurdles. |
|
|
APRIL'S BEST INDUSTRY INSIGHTS |
|
|
|
|
|
|
|
|
|
.png){kind=logo}